ImmunityBio, Inc. Common Stock
IBRXImmunityBio, Inc. (IBRX) is a biotechnology company focused on developing innovative immunotherapies and cancer treatments. The company specializes in next-generation immuno-oncology, aiming to enhance the body's immune response to fight cancer and infectious diseases through its proprietary platform technologies.
Company News
The article identifies the top 10 most heavily shorted stocks in the market as of January 16, 2026, with short interest ranging from 36-56%. These stocks are highlighted as potential candidates for short squeezes, where unexpected price increases force short sellers to cover positions, creating rapid gains. The list includes Choice Hotels Interna...
U.S. stock futures rose on Friday following Thursday's positive close, with chip stocks leading gains after Taiwan Semiconductor Manufacturing Co. posted record quarterly results. Financial stocks also rallied with Goldman Sachs and Morgan Stanley posting strong earnings. Key movers included Chevron expanding gas production, Paysafe forming a str...
ImmunityBio (IBRX) shares surged 28% on January 15, 2026, following announcement of exceptional preliminary 2025 financial results. The company reported approximately $113 million in net product revenue, a 700% year-over-year increase driven by accelerating adoption of its flagship immunotherapy drug ANKTIVA for bladder cancer. Q4 2025 revenue re...
ImmunityBio (IBRX) surged 30.80% on January 15, 2026, after reporting preliminary 2025 results showing Anktiva revenue jumped 700% to $113 million from $15 million in 2024. The bladder cancer therapy also demonstrated positive data for non-small cell lung cancer expansion and received approval in Saudi Arabia, driving investor optimism despite th...
A comprehensive report analyzing Q3 2025 CRO industry trends, focusing on clinical trial activities across different regions, therapeutic areas, and development phases.
